Managing Metastatic Bone Pain: The Role of Bisphosphonates

Journal of Pain and Symptom Management

Volumn 33, Issue 4, 2007, Pages 462-472

  Gralow, Julie ^a   Tripathy, Debu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; bone pain; clodronate; ibandronate; pamidronate; zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANALGESIC ACTIVITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PILOT STUDY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STANDARD; TREATMENT DURATION; TREATMENT PLANNING;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; PAIN; RANDOMIZED CONTROLLED TRIALS;

EID: 33947610096     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.01.001     Document Type: Review

References (67)

1. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 1-2 (1997) 1-18
2. Janjan N. Bone metastases: approaches to management. Semin Oncol 28 4 Suppl 11 (2001) 28-34
3. Serafini A.N. Therapy of metastatic bone pain. J Nucl Med 42 (2001) 895-906
4. Fulfaro F., Casuccio A., Ticozzi C., and Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78 (1998) 157-169
5. Yau V., Chow E., Davis L., et al. Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 27 (2004) 1-3
6. Twycross R.G. Management of pain in skeletal metastases. Clin Orthop 312 (1995) 187-196
7. Johnson G., Gralow J., and Benson P. Use of bisphosphonates for the palliative management of metastatic bone pain in the US. [abstract]. Support Care Cancer 12 (2004) 400 (A-105)
8. World Health Organization. Cancer pain relief and palliative care: Report of a WHO expert committee (1990), World Health Organization, Geneva, Switzerland
9. Body J.J., Bartl R., Burckhardt P., et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16 (1998) 3890-3899
10. Body J.J. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 12 Suppl 2 (2003) S37-S44
11. Pavlakis N., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2002) CD003474
12. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
13. Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 29 6 Suppl 21 (2002) 19-27
14. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., and Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465-473
15. Berruti A., Dogliotti L., Tucci M., et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 166 (2001) 2023-2031
16. Clarke N.W., McClure J., and George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68 (1991) 74-80
17. Garnero P., Buchs N., Zekri J., et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858-864
18. Percival R.C., Unwin G.H., Harris S., et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13 (1987) 41-49
19. Tubiana-Hulin M., Beuzeboc P., Mauriac L., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. [in French]. Bull Cancer 88 (2001) 701-707
20. McCloskey E.V., MacLennan I.C., Drayson M.T., et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100 (1998) 317-325
21. Robertson A.G., Reed N.S., and Ralston S.H. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13 (1995) 2427-2430
22. Jagdev S.P., Purohit O.P., Heatley S., Herling C., and Coleman R.E. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12 (2001) 1433-1438
23. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 (1998) 2038-2044
24. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17 (1999) 846-854
25. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
26. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with i.v. pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14 (1996) 2552-2559
27. Berenson J.R., Lichenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488-493
28. Small E.J., Smith M.R., Seaman J.J., Petrone S., and Kowalski M.O. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21 (2003) 4277-4284
29. Rosen L.S., Gordon D.H., Dugan W., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 (2004) 36-43
30. Saad F., Eastham J., McKiernan J., et al. Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases. [Abstract 572]. Eur Urol 4 Suppl (2005) 145
31. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
32. Weinfurt K.P., Li Y., Castel L.D., et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16 (2006) 579-584
33. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21 (2003) 3150-3157
34. Kohno N., Aogi K., Minami H., et al. Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer. [Abstract 3060]. Breast Cancer Res Treat 88 Suppl 1 (2004) S133
35. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
36. Fulfaro F., Arcara C., Badalamenti G., et al. The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer. [Abstract 1721]. J Clin Oncol 22 Suppl (2003) 428
37. Kretzschmar A., Wiegel T., Al-Batran S.-E., et al. Zoledronic acid as supportive treatment in cancer patients with bone lesions: results of a prospective, open-label trial with pain intensity and analgesic consumption as primary outcome. [Abstract 848P]. Ann Oncol 15 Suppl 3 (2004) iii223
38. Vogel C.L., Yanagihara R.H., Wood A.J., et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9 (2004) 687-695
39. Wardley A., Davidson N., Barrett-Lee P., et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized crossover study of community vs. hospital bisphosphonate administration. Br J Cancer 92 (2005) 1869-1876
40. Carteni G., Bordonaro R., Giotta F., et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 11 (2006) 841-848
41. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
42. Diel I.J., Body J.J., Lichinitzer M.R., et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40 (2004) 1704-1712
43. Body J.J., Diel I.J., Lichinitser M.R., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 90 (2004) 1133-1137
44. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
45. Menssen H.D., Sakalová A., Fontana A., et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20 (2002) 2353-2359
46. Body J.J. Is ibandronate effective in multiple myeloma?. Eur J Haematol 71 (2003) 470-472
47. Pfister T., Atzpodien E., and Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191 2-3 (2003) 159-167
48. Pfister T., Bauss F., and Body J.J. The risk of cumulative renal effects of intravenous (i.v.) bisphosphonates. [Abstract 859P]. Ann Oncol 15 Suppl 3 (2004) iii226
49. Mancini I., Dumon J.C., and Body J.J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22 (2004) 3587-3592
50. Heidenreich A., Elert A., and Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5 (2002) 231-235
51. Ohlmann C., and Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. [Abstract A-38]. Support Care Cancer 11 (2003) 396
52. Heidenreich A., Ohlmann C., Olbert P., and Hegele A. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1 Suppl 5 (2003) S270
53. Hillner B.E. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol 28 4 Suppl 11 (2001) 64-68
54. Vinholes J.J., Purohit O.P., Abbey M.E., Eastell R., and Coleman R.E. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 8 (1997) 1243-1250
55. Bonabello A., Galmozzi M.R., Bruzzese T., and Zara G.P. Analgesic effect of bisphosphonates in mice. Pain 91 (2001) 269-275
56. Mantyh P. Mechanisms of bone cancer pain relief with bisphosphonates. [Abstract 37]. Bone 38 3 Suppl 1 (2006) S56
57. Micke O., Berning D., Schäfer U., Bruns F., and Willich N. Combination of ibandronate and radiotherapy in metastatic bone disease-final results of a randomized phase II trial. Eur J Cancer 1 Suppl 5 (2003) S150
58. McPartland C., Jackson G., and Grosjean L. Palliative management of metastatic bone pain in Europe and Canada: the role of bisphosphonates. [abstract]. Support Care Cancer 12 (2004) 401-402 (A-110)
59. Migliorati C., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 136 (2005) 1658-1668
60. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging complication of supportive cancer therapy. Cancer 104 (2005) 83-93
61. Cleeland C.S., Janjan N.A., Scott C.B., Seiferheld W.F., and Curran W.J. Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys 47 (2000) 203-208
62. Neri B., Gemelli M.T., Sambataro S., et al. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs 3 (1992) 87-90
63. Shparik J. Intravenous clodronate for metastatic bone pain in breast cancer. Breast Cancer Res Treat 37 Suppl (1996) 75
64. Falchi A.M., Parmiggiani M., Cioni K., et al. Clodronate in the treatment of bone metastases secondary to breast cancer. Tumori 77 Suppl (1991) 99 Abstract 295
65. Ernst D.S., Brasher P., Hagen N., et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13 (1997) 319-326
66. Heidenreich A., Hofmann R., and Engelmann U.H. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165 (2001) 136-140
67. Coleman R., Purohit O.P., Vinholes J.J., and Zekri J. High dose pamidronate. Clinical and biochemical effects in metastatic bone disease. Cancer 80 8 Suppl (1997) 1686-1690